Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001193125-26-014129·Century Therapeutics, Inc.
Schedule 13G ownership disclosure
Century Therapeutics, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 15673T100
Event date: 2026-01-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- TCG Crossover GP II, LLC
Shares: 8,877,215 · Class: 4.9%
- TCG Crossover Fund II, L.P.
Shares: 8,877,215 · Class: 4.9%
- TCG Crossover GP III, LLC
Shares: 8,877,215 · Class: 4.9%
- TCG Crossover Fund III, L.P.
Shares: 8,877,215 · Class: 4.9%
- Chen Yu
Shares: 17,754,430 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-014129
- Form type
- SCHEDULE 13G
- Filer
- Century Therapeutics, Inc.
- CIK
- CIK 1850119
- Filed
- Jan 15, 2026
- Reporting period
- Jan 09, 2026
- Description
- Schedule 13G beneficial ownership